Loading...
Header Logo
Keywords
Last Name
KP Region

Jessica Ezzell Hunter, PhD

TitleInvestigator
InstitutionKaiser Permanente Northwest
DepartmentCenter for Health Research - Northwest
ORCID ORCID Icon0000-0002-1117-1097 Additional info
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Jessica Hunter is a genetic epidemiologist with training in molecular genetics, biostatistics, and neuropsychological outcomes. Her research focuses on the impact that genomic variation has on health outcomes and the neuropsychological and neuropsychiatric outcomes associated with specific genes.

    At the Center for Health Research, Dr. Hunter has worked on evidence-based assessments of clinical actionability associated with genome variation, the perspectives and attitudes of patients with colorectal cancer on universal tumor screening for Lynch syndrome, and the involvement of pharmacogenetics on osteoporotic hip fractures.

    Dr. Hunter joined CHR in 2013 following postdoctoral training at Emory University and Oregon Health & Science University. She earned her doctorate in genetics and molecular biology from Emory University and her master’s degree in human genetics from Tulane University.

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Paquin RS, Mittendorf KF, Lewis MA, Hunter JE, Lee K, Berg JS, Williams MS, Goddard KAB. Expert and lay perspectives on burden, risk, tolerability, and acceptability of clinical interventions for genetic disorders. Genet Med. 2019 Apr 26. PMID: 31028355.
      View in: PubMed
    2. Hunter JE, Jenkins CL, Grim V, Leung S, Charen KH, Hamilton DR, Allen EG, Sherman SL. Feasibility of an app-based mindfulness intervention among women with an FMR1 premutation experiencing maternal stress. Res Dev Disabil. 2019 Jun; 89:76-82. PMID: 30959430.
      View in: PubMed
    3. Clarke EV, Muessig KR, Zepp J, Hunter JE, Syngal S, Acheson LS, Wiesner GL, Peterson SK, Bergen KM, Shuster E, Davis JV, Schneider JL, Kauffman TL, Gilmore MJ, Reiss JA, Rope AF, Cook JE, Goddard KAB. Implementation of a Systematic Tumor Screening Program for Lynch Syndrome in an Integrated Health Care Setting. Fam Cancer. 2019 Feb 07. PMID: 30729418.
      View in: PubMed
    4. Webber EM, Hunter JE, Biesecker LG, Buchanan AH, Clarke EV, Currey E, Dagan-Rosenfeld O, Lee K, Lindor NM, Martin CL, Milosavljevic A, Mittendorf KF, Muessig KR, O'Daniel JM, Patel RY, Ramos EM, Rego S, Slavotinek AM, Sobriera NLM, Weaver MA, Williams MS, Evans JP, Goddard KAB. Evidence-based assessments of clinical actionability in the context of secondary findings: Updates from ClinGen's Actionability Working Group. Hum Mutat. 2018 Nov; 39(11):1677-1685. PMID: 30311382.
      View in: PubMed
    5. Rahm AK, Cragun D, Hunter JE, Epstein MM, Lowery J, Lu CY, Pawloski PA, Sharaf RN, Liang SY, Burnett-Hartman AN, Gudgeon JM, Hao J, Snyder S, Gogoi R, Ladd I, Williams MS. Implementing universal Lynch syndrome screening (IMPULSS): protocol for a multi-site study to identify strategies to implement, adapt, and sustain genomic medicine programs in different organizational contexts. BMC Health Serv Res. 2018 Oct 30; 18(1):824. PMID: 30376847.
      View in: PubMed
    6. Schneider JL, Goddard KAB, Muessig KR, Davis JV, Rope AF, Hunter JE, Peterson SK, Acheson LS, Syngal S, Wiesner GL, Reiss JA. Patient and provider perspectives on adherence to and care coordination of lynch syndrome surveillance recommendations: findings from qualitative interviews. Hered Cancer Clin Pract. 2018; 16:11. PMID: 29760830.
      View in: PubMed
    7. Hunter JE, Arnold KA, Cook JE, Zepp J, Gilmore MJ, Rope AF, Davis JV, Bergen KM, Esterberg E, Muessig KR, Peterson SK, Syngal S, Acheson L, Wiesner G, Reiss J, Goddard KAB. Universal screening for Lynch syndrome among patients with colorectal cancer: patient perspectives on screening and sharing results with at-risk relatives. Fam Cancer. 2017 07; 16(3):377-387. PMID: 28176204.
      View in: PubMed
    8. Hunter JE, Irving SA, Biesecker LG, Buchanan A, Jensen B, Lee K, Martin CL, Milko L, Muessig K, Niehaus AD, O'Daniel J, Piper MA, Ramos EM, Schully SD, Scott AF, Slavotinek A, Sobreira N, Strande N, Weaver M, Webber EM, Williams MS, Berg JS, Evans JP, Goddard KA. A standardized, evidence-based protocol to assess clinical actionability of genetic disorders associated with genomic variation. Genet Med. 2016 12; 18(12):1258-1268. PMID: 27124788.
      View in: PubMed
    9. Winawer MR, Shih J, Beck ES, Hunter JE, Epstein MP. Genetic effects on sleep/wake variation of seizures. Epilepsia. 2016 Apr; 57(4):557-65. PMID: 26948972.
      View in: PubMed
    10. Hunter JE, Zepp JM, Gilmore MJ, Davis JV, Esterberg EJ, Muessig KR, Peterson SK, Syngal S, Acheson LS, Wiesner GL, Reiss JA, Goddard KA. Universal tumor screening for Lynch syndrome: Assessment of the perspectives of patients with colorectal cancer regarding benefits and barriers. Cancer. 2015 Sep 15; 121(18):3281-9. PMID: 26036338.
      View in: PubMed
    11. Visootsak J, Huddleston L, Buterbaugh A, Perkins A, Sherman S, Hunter J. Influence of CHDs on psycho-social and neurodevelopmental outcomes in children with Down syndrome. Cardiol Young. 2016 Feb; 26(2):250-6. PMID: 25683160.
      View in: PubMed
    12. Hunter J, Rivero-Arias O, Angelov A, Kim E, Fotheringham I, Leal J. Epidemiology of fragile X syndrome: a systematic review and meta-analysis. Am J Med Genet A. 2014 Jul; 164A(7):1648-58. PMID: 24700618.
      View in: PubMed
    13. Hunter JE, Allen EG, Shin M, Bean LJ, Correa A, Druschel C, Hobbs CA, O'Leary LA, Romitti PA, Royle MH, Torfs CP, Freeman SB, Sherman SL. The association of low socioeconomic status and the risk of having a child with Down syndrome: a report from the National Down Syndrome Project. Genet Med. 2013 Sep; 15(9):698-705. PMID: 23558253.
      View in: PubMed
    14. Ferguson B, Hunter JE, Luty J, Street SL, Woodall A, Grant KA. Genetic load is associated with hypothalamic-pituitary-adrenal axis dysregulation in macaques. Genes Brain Behav. 2012 Nov; 11(8):949-57. PMID: 22998353.
      View in: PubMed
    15. Hunter JE, Leslie M, Novak G, Hamilton D, Shubeck L, Charen K, Abramowitz A, Epstein MP, Lori A, Binder E, Cubells JF, Sherman SL. Depression and anxiety symptoms among women who carry the FMR1 premutation: impact of raising a child with fragile X syndrome is moderated by CRHR1 polymorphisms. Am J Med Genet B Neuropsychiatr Genet. 2012 Jul; 159B(5):549-59. PMID: 22573456.
      View in: PubMed
    16. Hunter JE, Sherman S, Grigsby J, Kogan C, Cornish K. Capturing the fragile X premutation phenotypes: a collaborative effort across multiple cohorts. Neuropsychology. 2012 Mar; 26(2):156-64. PMID: 22251309.
      View in: PubMed
    17. Hunter JE, Epstein MP, Tinker SW, Abramowitz A, Sherman SL. The FMR1 premutation and attention-deficit hyperactivity disorder (ADHD): evidence for a complex inheritance. Behav Genet. 2012 May; 42(3):415-22. PMID: 22101959.
      View in: PubMed
    18. Allen EG, Hunter JE, Rusin M, Juncos J, Novak G, Hamilton D, Shubeck L, Charen K, Sherman SL. Neuropsychological findings from older premutation carrier males and their noncarrier siblings from families with fragile X syndrome. Neuropsychology. 2011 May; 25(3):404-411. PMID: 21443343.
      View in: PubMed
    19. Bottomly D, Walter NA, Hunter JE, Darakjian P, Kawane S, Buck KJ, Searles RP, Mooney M, McWeeney SK, Hitzemann R. Evaluating gene expression in C57BL/6J and DBA/2J mouse striatum using RNA-Seq and microarrays. PLoS One. 2011 Mar 24; 6(3):e17820. PMID: 21455293.
      View in: PubMed
    20. Hunter JE, Rohr JK, Sherman SL. Co-occurring diagnoses among FMR1 premutation allele carriers. Clin Genet. 2010 Apr; 77(4):374-81. PMID: 20059484.
      View in: PubMed
    21. Epstein MP, Hunter JE, Allen EG, Sherman SL, Lin X, Boehnke M. A Variance-Component Framework for Pedigree Analysis of Continuous and Categorical Outcomes. Stat Biosci. 2009 Nov; 1(2):181-198. PMID: 20436936.
      View in: PubMed
    22. Tang B, Dutt K, Papale L, Rusconi R, Shankar A, Hunter J, Tufik S, Yu FH, Catterall WA, Mantegazza M, Goldin AL, Escayg A. A BAC transgenic mouse model reveals neuron subtype-specific effects of a Generalized Epilepsy with Febrile Seizures Plus (GEFS+) mutation. Neurobiol Dis. 2009 Jul; 35(1):91-102. PMID: 19409490.
      View in: PubMed
    23. Hunter JE, Abramowitz A, Rusin M, Sherman SL. Is there evidence for neuropsychological and neurobehavioral phenotypes among adults without FXTAS who carry the FMR1 premutation? A review of current literature. Genet Med. 2009 Feb; 11(2):79-89. PMID: 19265746.
      View in: PubMed
    24. Hunter JE, Allen EG, Abramowitz A, Rusin M, Leslie M, Novak G, Hamilton D, Shubeck L, Charen K, Sherman SL. No evidence for a difference in neuropsychological profile among carriers and noncarriers of the FMR1 premutation in adults under the age of 50. Am J Hum Genet. 2008 Dec; 83(6):692-702. PMID: 19026394.
      View in: PubMed
    25. Hunter JE, Epstein MP, Tinker SW, Charen KH, Sherman SL. Fragile X-associated primary ovarian insufficiency: evidence for additional genetic contributions to severity. Genet Epidemiol. 2008 Sep; 32(6):553-9. PMID: 18357616.
      View in: PubMed
    26. Hunter JE, Allen EG, Abramowitz A, Rusin M, Leslie M, Novak G, Hamilton D, Shubeck L, Charen K, Sherman SL. Investigation of phenotypes associated with mood and anxiety among male and female fragile X premutation carriers. Behav Genet. 2008 Sep; 38(5):493-502. PMID: 18535897.
      View in: PubMed
    27. Hunter J, Maljevic S, Shankar A, Siegel A, Weissman B, Holt P, Olson L, Lerche H, Escayg A. Subthreshold changes of voltage-dependent activation of the K(V)7.2 channel in neonatal epilepsy. Neurobiol Dis. 2006 Oct; 24(1):194-201. PMID: 16916607.
      View in: PubMed
    28. Barela AJ, Waddy SP, Lickfett JG, Hunter J, Anido A, Helmers SL, Goldin AL, Escayg A. An epilepsy mutation in the sodium channel SCN1A that decreases channel excitability. J Neurosci. 2006 Mar 08; 26(10):2714-23. PMID: 16525050.
      View in: PubMed
    Hunter's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description

    © 2019 Kaiser Permanente

    KP Researcher Profiles is funded by Kaiser Permanente Research.